Biocon has launched Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.
The launch of Tacrolimus capsules, following an approval from the United States Food and Drug Administration (USFDA) in November 2020, underscores Biocon’s relentless pursuit of its mission to make affordable healthcare accessible. The launch of Tacrolimus capsules in the US is another milestone for Biocon that reflects commitment to continually evaluate and expand portfolio of complex products to serve patients.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
